Indo Us Biotech Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indo Us Biotech Limited informed the exchanges that its Board of Directors met on August 12, 2025, and approved the unaudited standalone financial results for the quarter ended June 30, 2025 (Q1 FY26), along with the limited review report from statutory auditor Gautam N Associates. The board meeting was brief, running from 2:00 PM to 2:30 PM, and no other major business items were tabled. The financial tables in the filing are largely unreadable due to scanning quality, so specific revenue and profit figures cannot be reliably reported. The auditor issued a clean limited review report with no qualifications.
This is a routine regulatory filing required under SEBI's Listing Regulations. With no other business decisions (such as fundraising, dividend, or expansion) announced, the market impact is likely neutral. Shareholders should look at the detailed Q1 numbers separately for actual performance signals.